Oncolytics Biotech Stock Today
| ONCY Stock | USD 0.95 0.03 3.06% |
Performance1 of 100
| Odds Of DistressLess than 9
|
Oncolytics Biotech is trading at 0.95 as of the 25th of November 2024; that is 3.06 percent decrease since the beginning of the trading day. The stock's open price was 0.98. Oncolytics Biotech has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat weak performance during the last 90 days. Equity ratings for Oncolytics Biotech are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of October 2024 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of November 1999 | Category Healthcare | Classification Health Care |
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada. Oncolytics Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 77.07 M outstanding shares of which 2.81 M shares are now shorted by private and institutional investors with about 3.51 trading days to cover. More on Oncolytics Biotech
Moving together with Oncolytics Stock
Moving against Oncolytics Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Oncolytics Stock Highlights
| CEO President | Dr MBA | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsOncolytics Biotech can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Oncolytics Biotech's financial leverage. It provides some insight into what part of Oncolytics Biotech's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Oncolytics Biotech (ONCY) is traded on NASDAQ Exchange in USA. It is located in 322 11th Avenue SW, Calgary, AB, Canada, T2R 0C5 and employs 13 people. Oncolytics Biotech is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 73.54 M. Oncolytics Biotech conducts business under Biotechnology sector and is part of Health Care industry. The entity has 77.07 M outstanding shares of which 2.81 M shares are now shorted by private and institutional investors with about 3.51 trading days to cover.
Oncolytics Biotech currently holds about 32.36 M in cash with (28.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.55.
Check Oncolytics Biotech Probability Of Bankruptcy
Ownership AllocationOncolytics Biotech owns a total of 77.07 Million outstanding shares. Oncolytics Biotech holds 3.81 pct. of its outstanding shares held by insiders and 1.76 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Oncolytics Ownership Details
Oncolytics Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Bmo Capital Markets Corp. | 2024-06-30 | 37.4 K | |
| Virtu Financial Llc | 2024-06-30 | 27.4 K | |
| Brave Asset Management Inc | 2024-09-30 | 25 K | |
| Newman Dignan & Sheerar Inc | 2024-09-30 | 22 K | |
| Financial Advisory Corp /ut/ /adv | 2024-09-30 | 20.6 K | |
| Lpl Financial Corp | 2024-09-30 | 20.5 K | |
| Head & Associates, Llc | 2024-09-30 | 17.4 K | |
| C2p Capital Advisory Group Llc Dba Prosperity Capital Advisors | 2024-09-30 | 15 K | |
| Ausdal Financial Partners Inc | 2024-09-30 | 14 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 277 K | |
| Seeds Investor Llc | 2024-09-30 | 189.9 K |
Oncolytics Biotech Historical Income Statement
Oncolytics Stock Against Markets
Oncolytics Biotech Corporate Management
| Amy Levin | Vice Operations | Profile | |
| FCA FCA | Consultant | Profile | |
| Jon Patton | Director Communication | Profile | |
| FACP FACP | Consultant | Profile | |
| Wayne MBA | Interim Board | Profile | |
| Andrew Guttadauro | Global Inc | Profile |
Additional Tools for Oncolytics Stock Analysis
When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.